Since 1985 we have manufactured and distributed leading-edge ophthalmic laser and imaging technology for use in the fight against blindness. Today, more than 20,000 Ellex ophthalmic laser and ultrasound systems are in use worldwide. We also offer a range of third-party medical devices and technologies.

CLICK HERE TO LEARN ABOUT THE ELLEX PRODUCT PORTFOLIO

The latest addition to the Ellex product family is Canaloplasty; a restorative surgical procedure, which uses patented microcatheter technology to restore the eye’s natural outflow pathways in the treatment of glaucoma.

CLICK HERE TO LEARN MORE ABOUT CANALOPLASTY
Our Manufacturing Expertise is Our Greatest Asset

Our state-of-the-art manufacturing facility employs the latest production techniques and a team of highly trained technicians specialized in opto-electronics. Recognized as the short-pulsed laser experts, some of the industry’s largest companies including Coherent (now Lumenis) have entrusted us to manufacture their ophthalmic lasers. Over the years Ellex has evolved from a manufacturing company of primarily original equipment manufacture (OEM) products, to direct marketing of our own branded products and services through subsidiaries in the United States, Japan, Germany, France and Australia, and a network of distribution partners in more than 100 countries.

CLICK HERE TO READ ABOUT OUR EVOLUTION IN OPHTHALMOLOGY
A Commitment to Customer Care

The Ellex name has long been synonymous with excellence in technology, in quality, and in customer care. We maintain the highest quality standards through product development and manufacturing, and strive to provide unmatched levels of clinical expertise and support to our customers. All of these efforts have combined to produce one of the highest levels of customer satisfaction in the medical industry.
Ophthalmic Research: Pushing the Envelope

Ellex maintains a strong emphasis on intellectual property and research into new and better treatments for ophthalmic disease. We are constantly pushing the envelope in terms of what ophthalmic technology can accomplish. Among our current research efforts is 2RT™ (also known as Retinal Rejuvenation Therapy), a breakthrough laser procedure currently undergoing clinical trial for early Age-Related Macular Degeneration (AMD). Unlike currently marketed treatments for AMD, which only treat the late stages of the disease, 2RT™ offers the potential to intervene much earlier before significant vision loss occurs.